🔎 Trials Near Me

Hjem › Metastatisk kreft › Kentucky › Lexington

Kliniske studier for Metastatisk kreft i Lexington, KY

11 studier for Metastatisk kreft søker deltakere på steder i og rundt Lexington (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.

Offisiell studietekst (engelsk)

Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

RekruttererFase 2
  • CommonSpirit Saint Joseph Medical Center - East Lexington, Lexington
  • University of Kentucky/Markey Cancer Center, Lexington
Alle aldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT05564377

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

RekruttererFase 1
  • University of Kentucky/Markey Cancer Center, Lexington
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05372614

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

RekruttererFase 2/3
  • University of Kentucky Markey Cancer Center, Lexington
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT06943755

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

RekruttererFase 3
  • Baptist Health Lexington, Lexington
  • Baptist Health Richmond, Lexington
  • Baptist Health Hamburg, Lexington
  • og 3 flere
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07222800

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

RekruttererFase 2/3
  • University of Kentucky Research Foundation, Lexington
  • University of Kentucky Healthcare - Markey Cancer Center, Lexington
  • University of Kentucky Medical Center, Lexington
  • og 1 flere
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06989437

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

RekruttererFase 3
  • Baptist Health Lexington, Lexington
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07213804

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

RekruttererFase 3
  • CHI Saint Joseph Cancer Center - East, Lexington
  • University of Kentucky Chandler Medical Center, Lexington
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT06119581

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

RekruttererFase 2
  • University of Kentucky/Markey Cancer Center, Lexington
Alder 18 og eldre · Alle kjønn · Oppdatert 4. sep. 2026 · NCT06311214

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

RekruttererFase 1/2
  • Crinetics Study Site, Lexington
Alder 18 og eldre · Alle kjønn · Oppdatert 31. jul. 2026 · NCT07129252

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

RekruttererFase 1
  • UK Markey Cancer Center, Lexington
Alder 18 og eldre · Alle kjønn · Oppdatert 11. jun. 2026 · NCT05283330

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

RekruttererFase 1
  • University of Kentucky Markey Cancer Center, Lexington
Alder 18 og eldre · Alle kjønn · Oppdatert 13. feb. 2026 · NCT06778863

Metastatisk kreft-studier i andre byer

Andre studier i Lexington

Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.